The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to iCell Gene Therapeutics‘ Chimeric Antigen Receptor (CAR) engineered T-cells targeting CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). ... Read more